Marker Therapeutics (MRKR) announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company’s Board of Directors, effective November 1, 2025. Most recently, Penkus Corzo served as President and Chief Operating Officer at bit.bio.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRKR:
- Marker Therapeutics’ Innovative Approach in AML and MDS Treatment: A Study Update
- Marker Therapeutics’ MT-601 Study: A Promising Step in Lymphoma Treatment
- Marker Therapeutics Advances Off-the-Shelf T Cell Therapy with First Patient Treatment
- Marker Therapeutics announces first patient treated in off-the-shelf program